Identification of severe potential drug-drug interactions using an Italian general-practitioner database

European Journal of Clinical Pharmacology

Volumn 64, Issue 3, 2008, Pages 303-309

  Magro, L ^a   Conforti, A ^a,d   Del Zotti, F ^b   Leone, R ^a   Iorio, M L ^a   Meneghelli, I ^a   Massignani, D ^c   Visona E ^c   Moretti, U ^a  

^a UNIVERSITY OF VERONA   (Italy)

^b Europ General Practice Research Network (EGPRN) Within World Organization of Family Doctor (WONCA)   (Netherlands)

^c Società Italiana Medicina Generale SIMG   (Italy)

^d Clinical Pharmacology Unit   (Italy)

Author keywords

General practice; Monitoring; Severe potential drug drug interactions

Indexed keywords

ACETYLSALICYLIC ACID; AMILORIDE; AMIODARONE; ATORVASTATIN; AZITHROMYCIN; DIGOXIN; ENALAPRIL; FUROSEMIDE; HYDROCHLOROTHIAZIDE; KETOROLAC; LEVOFLOXACIN; LISINOPRIL; LOSARTAN; PERINDOPRIL; PROPAFENONE; RAMIPRIL; SIMVASTATIN; SPIRONOLACTONE; VERAPAMIL; WARFARIN;

ADOLESCENT; ADULT; AGED; ARTICLE; CARDIOTOXICITY; CHILD; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG MONITORING; DRUG SAFETY; ELECTROCARDIOGRAPHY MONITORING; ELECTROLYTE DISTURBANCE; FEMALE; GENERAL PRACTITIONER; HEART ARRHYTHMIA; HUMAN; INFANT; ITALY; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MYOPATHY; PHARMACOEPIDEMIOLOGY; PRESCRIPTION; PRIORITY JOURNAL; REFERENCE DATABASE; RETROSPECTIVE STUDY; RHABDOMYOLYSIS; RISK ASSESSMENT;

ADOLESCENT; ADULT; ADVERSE DRUG REACTION REPORTING SYSTEMS; AGED; CHILD; CHILD, PRESCHOOL; DATABASES, FACTUAL; DRUG INTERACTIONS; DRUG MONITORING; FEMALE; HUMANS; INFANT; ITALY; MALE; MIDDLE AGED; PHYSICIAN'S PRACTICE PATTERNS; PHYSICIANS, FAMILY; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 43049159462     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-007-0394-1     Document Type: Article

References (50)

1. Tatro DS (ed) (2006) Drug interaction facts™-the authority on drug interactions. Facts and Comparisons, St. Louis, MO
2. Grönroos PE, Irjala KM, Huupponen RK, Scheinin H, Forsström J, Forsström JJ (1997) A medication database-a tool for detecting drug interactions in hospital. Eur J Clin Pharmacol 53(1):13-17
3. Glintborg B, Andersen SE, Dalhoff K (2005) Drug-drug interactions among recently hospitalized patients-frequent but mostly clinically insignificant. Eur J Clin Pharmacol 61(9):675-681
4. Cruciol-Souza JM, Thomson JC (2006) Prevalence of potential drug-drug interactions and its associated factors in a Brazilian teaching hospital. J Pharm Pharm Sci 9(3):427-433
5. Bjerrum L, Andersen M, Petersen G, Kragstrup J (2003) Exposure to potential drug interactions in primary health care. Scand J Prim Health Care 21(3):153-158
6. Jankel CA, Speedie SM (1990) Detecting drug interactions: a review of the literature. DICP 24(10):982-989
7. Björkman IK, Fastbom J, Schmidt IK, Bernsten CB, Pharmaceutical Care of the Elderly in Europe Research (PEER) Group (2002) Drug-drug interactions in the elderly. Ann Pharmacother 36(11):1675-1681
8. Bergendal L, Friberg A, Schaffrath A (1995) Potential drug-drug interactions in 5,125 mostly elderly out-patients in Gothenburg, Sweden. Pharm World Sci 17(5):152-157
9. Costa AJ (1991) Potential drug interactions in an ambulatory geriatric population. Fam Pract 8(3):234-236
10. Rosholm JU, Bjerrum L, Hallas J, Worm J, Gram LF (1998) Polypharmacy and the risk of drug-drug interactions among Danish elderly. A prescription database study. Dan Med Bull 45(2):210-213
11. Guèdon-Moreau L, Ducrocq D, Duc MF, Quieureux Y, L'Hôte C, Deligne J, Caron J (2004) Absolute contraindications in relation to potential drug interactions in outpatient prescriptions: analysis of the first five million prescriptions in 1999. Eur J Clin Pharmacol 59(12):899-904
12. Astrand B, Astrand E, Antonov K, Petersson G (2006) Detections of potential drug interactions-a model for a national pharmacy register. Eur J Clin Pharmacol 62(9):749-756
13. Steiness E, Olesen KH (1976) Cardiac arrhythmias induced by hypokalaemia and potassium loss during maintenance digoxin therapy. Br Heart J 38(2):167-172
14. Schepkens H, Vanholder R, Billiouw JM, Lameire N (2001) Life-threatening hyperkalemia during combined therapy with angiotensin-converting enzyme inhibitors and spironolactone: an analysis of 25 cases. Am J Med 110(6):438-441
15. Janchawee B, Owatranporn T, Mahatthanatrakul W, Chongsuvivatwong V (2005) Clinical drug interactions in outpatients of a university hospital in Thailand. J Clin Pharm Ther 30(6):583-590
16. Egger SS, Drewe J, Schlienger RG (2003) Potential drug-drug interactions in the medication of medical patients at hospital discharge. Eur J Clin Pharmacol 58(11):773-778
17. Becker ML, Kallewaard M, Caspers PW, Visser LE, Leufkens HG, Stricker BH (2006) Hospitalisations and emergency department visits due to drug-drug interactions: a literature review. Pharmacoepidemiol Drug Saf 16(6):641-651
18. Doucet J, Chassagne P, Trivalle C, Landrin I, Pauty MD, Kadri N, Mènard JF, Bercoff E (1996) Drug-drug interactions related to hospital admissions in older adults: a prospective study of 1000 patients. J Am Geriatr Soc 44(8):944-948
19. McDonnell PJ, Jacobs MR (2002) Hospital admissions resulting from preventable adverse drug reactions. Ann Pharmacother 36(9):1331-1336
20. Vitry AI (2006) Comparative assessment of four drug interaction compendia. Br J Clin Pharmacol 63(6):709-714
21. Il Pensiero Scientifico (Ed) (2005) L'uso dei Farmaci in Italia-Rapporto Nazionale anno 2004. OsMed (Osservatorio Nazionale sull'Impiego dei Medicinali), Rome
22. Fux R, Greiner D, Geldmacher M, Mörike K, Gleiter CH (2006) Multiple drug prescribing by general practitioners in a German region: implications for drug interactions and patient safety. Int J Clin Pharmacol Ther 44(11):539-547
23. The Digitalis Investigation Group (1997) The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 336(8):525-533
24. Ahmed A, Rich MW, Love TE, Lloyd-Jones DM, Aban IB, Colucci WS, Adams KF, Gheorghiade M (2006) Digoxin and reduction in mortality and hospitalization in heart failure: a comprehensive post hoc analysis of the DIG trial. Eur Heart J 27(2):178-186
25. Hunt SA, American College of Cardiology, American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure) (2005) ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). J Am Coll Cardiol 46(6):e1-e82
26. Adams KF, Gheorghiade M, Uretsky BF, Patterson JH, Schwartz TA, Young JB (2002) Clinical benefits of low serum digoxin concentrations in heart failure. J Am Coll Cardiol 39(6):946-953
27. Whang R, Oei TO, Watanabe A (1985) Frequency of hypomagnesaemia in hospitalized patients receiving digitalis. Arch Inter Med 145(4):655-656
28. Belz GG, Doering W, Munkes R, Matthews J (1983) Interaction between digoxin and calcium antagonists and antiarrhythmic drugs. Clin Pharmacol Ther 33(4):410-417
29. Lehmann HU, Witt E, Temmen L, Hochrein H (1978) Life-threatening digitalis intoxication with and without additional diuretic treatment. Dtsch Med Wochenschr 103(40):1566-1571
30. Eichhorn EJ, Gheorghiade M (2002) Digoxin. Prog Cardiovasc Dis 44(4):251-266
31. Smith TW, Antman EM, Friedman PL, Blatt CM, Marsh JD (1984) Digitalis glycosides: mechanism and manifestations of toxicity. Parts I and II. Prog Cardiovasc Dis 26(5):413-458; 26 (6):495-540
32. Oetgen WJ, Sobol SM, Tri TB, Heydon WH, Rakita L (1984) Amiodarone-digoxin interaction. Clinical and experimental observations. Chest 86(1):75-79
33. Nademanee K, Kannan R, Hendrickson J, Ookhtens M, Kay I, Singh BN (1984) Amiodarone-digoxin interaction: clinical significance, time course of development, potential pharmacokinetic mechanisms and therapeutic implications. J Am Coll Cardiol 4(1):111-116
34. Pedersen KE, Christiansen BD, Kjaer K, Klitgaard NA, Nielsen-Kudsk F (1983) Verapamil-induced changes in digoxin kinetics and intraerythrocytic sodium concentration. Clin Pharmacol Ther 34(1):8-13
35. Schwartz JB, Keefe D, Kates RE, Kirsten E, Harrison DC (1982) Acute and chronic pharmacodynamic interaction of verapamil and digoxin in atrial fibrillation. Circulation 65(6):1163-1170
36. Klein HO, Lang R, Weiss E, Di Segni E, Libhaber C, Guerriero J, Kaplinsky E (1982) The influence of verapamil on serum digoxin concentration. Circulation 65(5):998-1003
37. Magnani B, Malini PL (1995) Cardiac glycosides. Drug interactions of clinical significance. Drug Saf 12(2):97-109
38. Wrenger E, Müller R, Moesenthin M, Welte T, Frölich JC, Neumann KH (2003) Interaction of spironolactone with ACE-inhibitors or angiotensin receptor blockers: analysis of 44 cases. BMJ 327(7407):147-149
39. Simborg DW (1976) Medication prescribing on a university medical service-the incidence of drug combinations with potential adverse interactions. Johns Hopkins Med J 139(1):23-26
40. Johnston RT, de Bono DP, Nyman CR (1992) Preventable sudden death in patients receiving angiotensin converting enzyme inhibitors and loop/potassium sparing diuretic combinations. Int J Cardiol 34(2):213-215
41. Reardon LC, Macpherson DS (1998) Hyperkalemia in outpatients using angiotensin-converting enzyme inhibitors. Arch Intern Med 158(1):26-32
42. Kurnik D, Loebstein R, Farfel Z, Ezra D, Halkin H, Olchovsky D (2004) Complex drug-drug-disease interactions between amiodarone, warfarin, and the thyroid gland. Medicine (Baltimore) 83(2):107-113
43. Farmer JA, Torre-Amione G (2000) Comparative tolerability of the HMG-CoA reductase inhibitors. Drug Saf 23(3):197-213
44. Westphal JF (2000) Macrolide-induced clinically relevant drug interactions with cytochrome P-450A (CYP) 3A4: an update focused on clarithromycin, azithromycin and dirithromycin. Br J Clin Pharmacol 50(4):285-295
45. Amacher DE, Schomaker SJ, Retsema JA (1991) Comparison of the effects of the new azalide antibiotic, azithromycin, and erythromycin estolate on rat liver cytochrome P-450. Antimicrob Agents Chemother 35(6):1186-1190
46. Nahata M (1996) Drug interactions with azithromycin and the macrolides; an overview. J Antimicrobic Chemother 37(Suppl):133-142
47. Piacentini N, Trifirò G, Tari M, Moretti S, Arcoraci V, UVEC Group (2005) Statin-macrolide interaction risk: a population-based study throughout a general practice database. Eu J Clin Pharmacol 61(8):615-620
48. Stang P, Morris L, Kempf J, Henderson S, Yood MU, Oliveria S (2007) The coprescription of contraindicated drugs with statins: continuing potential for increased risk of adverse events. Am J Ther 14(1):30-40
49. Glassman PA, Simon B, Belperio P, Lanto A (2002) Improving recognition of drug interactions: benefits and barriers to using automated drug alerts. Med Care 40(12):1161-1171
50. Hansten PD (2003) Drug interaction management. Pharm World Sci 25(3):94-97